Hepatocellular carcinoma is the fifth most common tumor in the world and the third most fatal. Over the past decades, the incidence of this tumor has been increasing in the United States and Europe. In Lithuania, cases of hepatocellular carcinoma are also increasing. Liver tumours are expected to increase further over the next two decades. Scientists estimate that 60-70 % of patients can be cured, so timely diagnosis is very important. As a result, sensitive diagnostic systems are highly relevant to the world, which will help the doctor to diagnose the disease in a timely manner and to evaluate the prognosis of the disease and prescribe appropriate treatment._x000D_The current global diagnostic tests for hepatocellular carcinoma are non-sensitive and do not have a high specificity, so the disease is diagnosed in late stages. In the world, there is no molecular kit developed to confirm at an early stage or to rule out both diagnoses. Therefore, the development of such products helps to prevent late-stage tumors and cases of liver fibrosis in a non-invasive way._x000D_The project is planning to develop two completely new products for monitoring the digestive tract — (1) a set of molecular markers whose expression differences will have clinical significance for differentiating the hepatocellular carcinoma of the gastrointestinal system from malignant lesions, and (2) a molecular diagnostic kit allowing the detection of hepatic fibrosis.